Hematologic Malignancies

Isolated mild/moderate thrombocytopenia may not require intervention

1. In a review of children who presented to a specialist hematology clinic with isolated mild or moderate low platelet counts, though causes were variable, most required no interventions. 2. Pediatric patients with isolated mild or moderate thrombocytopenia may not need specialist referral to hematology in most circumstances. Evidence Rating Level: 2 (Good) Study Rundown: []

Navigating Patients with Hematologic Malignancies

Navigating Patients with Hematologic Malignancies

By

Patients with hematologic cancers often require a combination of inpatient and outpatient care. The oncology nurse navigator is an ideal care provider to help patients manage their care and transitions between care settings, according to a presentation at the 2018 ONA Navigation Summit.

Palliative Issues Inadequately Addressed Among Hospitalized Cancer Patients

Palliative Issues Inadequately Addressed Among Hospitalized Cancer Patients

By

Consultations for palliative care for hospitalized highly symptomatic patients with cancer is low regardless of curability or whether patient has hematologic or solid cancer, a study presented at 2018 ASCO has shown.

Online Program Aims to Assist With Clinical Trial Enrollment for Hematologic Cancers

Online Program Aims to Assist With Clinical Trial Enrollment for Hematologic Cancers

By

A newly developed web site, described in a presentation at the 2018 ONS Annual Congress, aims to help nurses and patients explore clinical trial options for patients with hematologic cancers.

Low Level Laser Therapy May Prevent Oral Mucositis During HSCT Conditioning

Low Level Laser Therapy May Prevent Oral Mucositis During HSCT Conditioning

By

Researchers assessed the effectiveness of low level laser therapy in preventing or minimizing oral mucositis in patients with hematologic cancers preparing to undergo HSCT. Results were presented at the 2018 ONS Annual Congress.

Class Preps Patients With AML for Successful At-Home Symptom Management and Self-Care

Class Preps Patients With AML for Successful At-Home Symptom Management and Self-Care

By

A presentation at 2018 ONS Congress described the success of a class focused on preparing patients and their families to management their care after discharge.

Nurse-led Interventions Improve Quality of Life for Lymphoma Survivors

Nurse-led Interventions Improve Quality of Life for Lymphoma Survivors

Patients with lymphoma were interviewed to determine their evaluation of a program that offered continuing clinical care with a nurse-led intervention in the early months of survivorship.

Management of Relapsed/Refractory Marginal Zone Lymphoma: Focus on Ibrutinib

Management of Relapsed/Refractory Marginal Zone Lymphoma: Focus on Ibrutinib

[Cancer Management and Research] A review of marginal zone lymphomas, a common and varied group of hematologic malignancies, and their treatment, with a focus on the Bruton's tyrosine kinase ibrutinib.

Taste Changes After Hematopoietic Stem Cell Transplant Affect QOL in Blood Cancers

Taste Changes After Hematopoietic Stem Cell Transplant Affect QOL in Blood Cancers

By

Slight changes in taste perceptions are noted in patients undergoing HSCT for hematologic cancers. In this study, researchers sought to determine how these changes affect quality of life and nutritional intake.

Intensified Reduced-Intensity Conditioning May Improve Outcomes in CBT

Intensified Reduced-Intensity Conditioning May Improve Outcomes in CBT

By

Researchers compared survival outcomes of thiotepa-based intensified RIC vs standard RIC among patients undergoing cord-blood transplantation (CBT).

Redefining Prognosis for Hematologic Cancers in Older Adults by Age

Redefining Prognosis for Hematologic Cancers in Older Adults by Age

By

A report on how variations in the effects of geriatric syndromes and aging can affect treatment modality choices and outcomes for the eldest older adults with hematologic cancers.

Outcomes for Elderly With Hematologic Cancers Effected by Cognitive Impairments

Outcomes for Elderly With Hematologic Cancers Effected by Cognitive Impairments

By

Study data suggest that cognitive impairments may be associate with worse survival among patients with hematologic cancer.

FDA Approves Fostamatinib for ITP After Insufficient Response to Previous Treatment

FDA Approves Fostamatinib for ITP After Insufficient Response to Previous Treatment

By

The US FDA granted approval to fostamatinib (Tavalisse), a kinase inhibitor, for the treatment of thrombocytopenia in patients with chronic IPT who have had an insufficient response to a previous treatment.

Elevated Pre-HCT Iron Levels Predictive of Worse Survival Outcomes in AML/MDS

Elevated Pre-HCT Iron Levels Predictive of Worse Survival Outcomes in AML/MDS

By

The ALLIVE trial sought to determine if eLPI levels were predictive of iron-related toxicity and mortality after HCT in patients with AML or MDS.

Patients Identify Critical Elements of Support in Hematologic Cancers

Patients Identify Critical Elements of Support in Hematologic Cancers

By

A cross-sectional study asked patients with hematologic cancers to name the components of care they felt were most crucial to their perception of optimal care.

Metformin Plus Ruxolitinib: A Potential Therapeutic Alternative for Myeloproliferative Neoplasms

Metformin Plus Ruxolitinib: A Potential Therapeutic Alternative for Myeloproliferative Neoplasms

By

Researchers investigated the antileukemic activity of metformin and ruxolitinib alone and in combination in patients with myeloproliferative neoplasms.

Bisphosphonate Therapy Underutilized in Multiple Myeloma Bone Disease Management

Bisphosphonate Therapy Underutilized in Multiple Myeloma Bone Disease Management

By

A retrospective study evaluated timing, frequency, dosing, and other factors related to bisphosphonate therapy in patients with multiple myeloma.

Self-efficacy Measure May Be Used to Drive Interventions Post-SCT in Hematologic Cancers

Self-efficacy Measure May Be Used to Drive Interventions Post-SCT in Hematologic Cancers

By

Researchers present findings of a study assessing the value of SESM evaluations in patients with hematologic cancer prior to undergoing SCT at the NACNS 2018 Annual Conference.

Cardiovascular Disease Risks Greater With ITP, Especially After Splenectomy

Cardiovascular Disease Risks Greater With ITP, Especially After Splenectomy

By

Idiopathic thrombocytopenic purpura (ITP) may be linked to an increased risk of cardiovascular disease, but studies have not been conclusive.

Pomalidomide Plus Dexamethasone Effective in R/R Multiple Myeloma

Pomalidomide Plus Dexamethasone Effective in R/R Multiple Myeloma

By

Researchers report on their findings of a retrospective study that compared pomalidomide plus dexamethasone vs dexamethasone alone in patients with relapsed/refractory multiple myeloma.

ITP Treatment Outcomes Not Improved With Intravenous vs Oral Corticosteroids

ITP Treatment Outcomes Not Improved With Intravenous vs Oral Corticosteroids

By

In this prospective study, researchers sought to compare the effectiveness of IV methylprednisolone vs oral prednisone in hospitalized patients with newly diagnosed ITP.

Fosfomycin Effective Alternate for Febrile Neutropenia Prophylaxis

Fosfomycin Effective Alternate for Febrile Neutropenia Prophylaxis

By

A retrospective chart study demonstrated the effectiveness of fosfomycin as an antibacterial prophylaxis for febrile neutropenia in patients with hematologic cancer.

High-Dose Dexamethasone Effective With Less Adverse Effects in ITP vs Corticosteroids

High-Dose Dexamethasone Effective With Less Adverse Effects in ITP vs Corticosteroids

By

In this randomized trial, investigators sought to determine the effectiveness of high-dose dexamethasone vs conventional prednisone therapy in treatment-naïve patients with ITP. Results were presented at ASH 2017.

Aspirin Does Not Reduce Risk of Venous Thromboembolism in Multiple Myeloma

Aspirin Does Not Reduce Risk of Venous Thromboembolism in Multiple Myeloma

By

A retrospective study, presented at ASH 2017, determined the effectiveness of aspirin in reducing risk of VTE in patients with multiple myeloma at high risk of developing VTE.

Ruxolitinib Beneficial in Hydroxyurea Resistant/Intolerant Polycythemia Vera

Ruxolitinib Beneficial in Hydroxyurea Resistant/Intolerant Polycythemia Vera

By

Data presented at ASH 2017 confirm that ruxolitinib improves hematocrit control, hematologic remission, and reduction in spleen size in some patients with polycythemia vera who fail hydroxyurea.

Ibrutinib Effective As First-line Therapy in Waldenström's Macroglobulinemia

Ibrutinib Effective As First-line Therapy in Waldenström's Macroglobulinemia

By

Ibrutinib — a Bruton tyrosine kinase inhibitor — is currently used among patients with WM who have previously received treatment. This prospective, phase 2 study sought to determine its efficacy as a first-line therapy in treatment-naive patients.

Prolonging Survival in MM: Daratumumab vs Pomalidomide Plus Dexamethasone

Prolonging Survival in MM: Daratumumab vs Pomalidomide Plus Dexamethasone

By

A head-to-head comparison investigated whether patients with multiple myeloma achieved greater prolongation in overall survival with daratumumab monotherapy or pomalidomide plus low-dose dexamethasone.

4R+3Dex Regimen May Lead to Durable Complete Response in Pediatric Chronic ITP

4R+3Dex Regimen May Lead to Durable Complete Response in Pediatric Chronic ITP

By

Young patients with chronic ITP may experience relapse within 5 years of completing therapy. In this study, investigators sought to determine if the 4R+3Dex regimen for chronic ITP would improve response rates in pediatric patients with the disease.

Response to Anemia Treatment Differs in Lymphoma, Multiple Myeloma

Response to Anemia Treatment Differs in Lymphoma, Multiple Myeloma

By

In this analysis, researchers measured the impact and effectiveness of supportive treatments for moderate to severe anemia in patients with lymphoma or multiple myeloma, based on patient-reported outcomes.

Vemurafenib Granted FDA Approval as First Drug to Treat Erdheim-Chester Disease

Vemurafenib Granted FDA Approval as First Drug to Treat Erdheim-Chester Disease

By

Indications for vemurafenib are expanded to include BRAF V600 mutation-positive Erdheim-Chester disease, an extremely rare non-Langerhans cell histiocytosis. FDA approval is based on results from the phase 2 VE-BASKET study.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs